**Overview**
Tavalisse (fostamatinib) is a small molecule prodrug of a tyrosine kinase inhibitor that inhibits the spleen tyrosine kinase (Syk). The major metabolite of fostamatinib, R406, is active in Syk inhibition. R406 is thought to increase the platelet count in patients with ITP.

**Coverage Guidelines**
Authorization may be granted when the following criteria are met:
1. Member is diagnosed with chronic immune thrombocytopenia (ITP)
2. Member is at least 18 years of age
3. Member has had an inadequate response or intolerance with corticosteroids and immunoglobulins or has not responded to a splenectomy
4. Member has had an inadequate response to maximally dosed Promacta (eltrombopag)
5. Member’s platelet count is < 30,000 microL to 50,000 microL
6. Member is experiencing significant symptomatic bleeding (e.g., mucous membrane, gastrointestinal)

**Continuation of Therapy**
Reauthorizations may be granted when clinical documentation is submitted showing improvement in the platelet count.

**Limitations**
1. Initial approvals will be granted for 6 months.
2. Reauthorizations will be granted for 12 months.

**References**
399 Revolution Drive, Suite 810, Somerville, MA 02145 | allwayshealthpartners.org

AllWays Health Partners includes AllWays Health Partners, Inc. and AllWays Health Partners Insurance Company
1. Tavalisse (fostamatinib) [prescribing information]. South San Francisco, CA: Rigel Pharmaceuticals, Inc; April 2018.
4. Promacta (eltrombopag) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals; November 2018. Iclusig (ponatinib) [prescribing information]. Cambridge, MA: Ariad Pharmaceuticals Inc; October 2018

**Review History**

04/17/19 – Reviewed

**Disclaimer**

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.